



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1989R1

Serial No.

10/697,142

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Semba Charles P.

Filing Date

30 Oct 2003

Group

Not Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

TU	70	Abbas, A. E., et al., "Intracoronary Fibrin-Specific Thrombolytic Infusion Facilitates Percutaneous Recanalization of Chronic Total Occlusion" <u>Journal of the American College of Cardiology</u> 46(5):793-798 (2005)
	71	Cairroll O.M., "Practical Application: Using Tissue Plasminogen Activator Overnight in Catheter Clearance on Tunnel Catheters Used for Hemodialysis" <u>Proceedings of the 22nd Annual Conference on Dialysis</u> 22(Suppl. 1):S56 (Mar 2002)
	72	Daeihagh, P., et al., "Efficacy of Tissue Plasminogen Activator Administration on Patency of Hemodialysis Access Catheters" <u>American Journal of Kidney Diseases</u> 36(1):75-79 (Jul 2000)
	73	Dowling, K., et al., "The Use of Tissue Plasminogen Activator Infusion to Re-establish Function of Tunneled Hemodialysis Catheters" <u>Nephrology Nursing Journal</u> 31(2):199-200 (March-April 2004)
	74	Eyrich, H., et al., "Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis" <u>Am. J. Health-Syst. Pharm.</u> 59:1437-1440 (Aug 1, 2002)
	75	Gibson, S. P., et al., "Five Years Experience with the Quinton Permcath for Vascular Access" <u>Nephrology Dialysis Transplantation</u> 6:269-274 (1991)
	76	Habowski, S.R. et al., "Use of Tissue Plasminogen Activator (t-PA) for Hemodialysis Catheter Malfunction" <u>J. Am. Soc. Nephrol.</u> 11:185A (2000)
	77	Hammes, M. S., et al., "Intraluminal Alteplase (t-PA) Is an Effective Means To Treat Occluded Hemodialysis (HD) Catheters" <u>J. Am. Soc. Nephrol.</u> 12:290A (2001)
	78	Little, M. A., et al., "A Longitudinal Study of the Repeated Use of Alteplase as Therapy for Tunneled Hemodialysis Catheter Dysfunction" <u>American Journal of Kidney Diseases</u> 39(1):86-91 (Jan 2002)
	79	Moss, A. H., et al., "Use of a Silicone Catheter With a Dacron Cuff for Dialysis Short-Term Vascular Access" <u>American Journal of Kidney Diseases</u> XII(6):492-498 (Dec 1988)
	80	National Kidney Foundation, "K/DOQI Clinical Practice Guidelines for Vascular Access, 2000" <u>Am J Kidney Dis</u> 37:S137-S181 (Suppl 1 2001)
	81	O'Mara, N.B., et al., "tPA for Central Vein Dialysis Catheter Patency" <u>J. Am. Soc. Nephrol.</u> 11:292A
	82	Refino, C. J., et al., "A Variant of Tissue Plasminogen Activator (T103N, N117Q, KHRR 296-299 AAAA) With a Decreased Plasma Clearance Rate is Substantially More Potent Than Activase rt-PA in a Rabbit Thrombolysis Model" <u>Thrombosis and Haemostasis, Abstracts edition</u> 69(6):841 (1993)
	83	Roberts, Nicole E. et al., "Outpatient Use of Alteplase (t-PA) in De-Clotting Dialysis Catheters" <u>J. Am. Soc. Nephrol</u> 11:195A (2000)
	84	Spry, L. A., et al., "Low-Dose tPA for Hemodialysis Catheter Clearance" <u>Dialysis & Transplantation</u> 30(1):10-13 (Jan 2001)
	85	Suhocki, P. V., et al., "Silastic Cuffed Catheters for Hemodialysis Vascular Access: Thrombolytic and Mechanical Correction of Malfunction" <u>American Journal of Kidney Diseases</u> 28(3):379-386 (Sep 1996)
	86	U.S. Renal Data System, <u>USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States</u> (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases), Bethesda, MD (2005)
	87	Zacharias, J.M., et al., "Alteplase Versus Urokinase for Occluded Hemodialysis Catheters" <u>The Annals of Pharmacotherapy</u> 37:27-33 (Jan 2003)

Examiner

/Thane Underdahl/

Date Considered

02/21/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

FEB 11 2004

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1989R1

Serial No.

10/697,142

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Semba Charles P.

Filing Date

30 Oct 2003

Group

Not Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
TU ↓	1	2001/0021811A1	13.09.01	Yock			
	2	5,612,029	18.03.97	Bennett et al.			
	3	5,849,736	15.12.98	Wityak et al.			
	4	5,865,178	02.02.99	Yock			
	5	6,346,517	12.02.02	Wong et al			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
TU ↓	6	WO 00/53264	14.09.00	PCT				
	7	WO 95/14683	01.06.95	PCT				
	8	WO 98/028326	02.07.98	PCT				


OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

TU ↓	9	Allie et al., "Novel Combination Thrombolytic Therapy in Limb Salvage: Mechanical Thrombectomy (Rheolytic Thrombectomy with Angiojet) and Chemical Thrombolysis (Tenecteplase) "Power-Pulse Spray" Technique" <u>Am. J. Cardiol.</u> 90:108H (2002)					
	10	Allie et al., "Tenecteplase in Peripheral Thrombolysis: Initial Safety and Feasibility Experience, abstract 48 of Society of Intervention Radiology" pps. S17 (Mar 2003)					
	11	Arepally et al., "Weight-based rt-PA Thrombolysis Protocol for Acute Native Arterial and Bypass Graft Occlusions" <u>J. Vasc. Interv. Radiol.</u> 13:45-50 (2002)					
	12	Assent-2 investigators, "Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators" <u>Lancet</u> 354:716-722 (1999)					
	13	Azmi-Ghadimi et al., "Use of Intraventricular Tissue Plasminogen Activator and Guglielmi Detachable Coiling for the Acute Treatment of Casted Ventricles from Cerebral Aneurysm Hemorrhage: Two Technical Case Reports" <u>Neurosurgery</u> 50:421-424 (2002)					
	14	Benedict et al., "New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA" <u>Circulation</u> 92(10):3032-3040 (1995)					
	15	Bookstein and Bookstein, "Augmented Experimental Pulse-Spray Thrombolysis with Tissue Plasminogen Activator, Enabling Dose Reduction by One or More Orders of Magnitude" <u>J. Vasc. Interv. Radiol.</u> 11:299-303 (2000)					
	16	Bookstein and Bookstein, "Plasminogen-enriched Pulse-Spray Thrombolysis with tPA: Further Developments" <u>J. Vasc. Interv. Radiol.</u> 11:1353-1362 (2000)					
	17	Burkart et al., "Thrombolysis of Acute Peripheral Arterial and Venous Occlusions with Tenecteplase and Eptifibatide: A Pilot Study" <u>J. Vasc. Interv. Radiol.</u> 14:729-733 (2003)					
	18	Burkart et al., "Thrombolysis of Occluded Peripheral Arteries and Veins with Tenecteplase: A Pilot Study" <u>J. Vasc. Interv. Radiol.</u> 13:1099-1102 (2002)					
	19	Calis et al., "Bioactivity of cryopreserved alteplase solutions" <u>Am. J. Health Syst. Pharm.</u> 56:2056-2057 (1999)					
	20	Castaneda et al., "Catheter-directed Thrombolysis in Deep Venous Thrombosis with Use of Reteplase: Immediate Results and Complications from a Pilot Study" <u>J. Vasc. Interv. Radiol.</u> 13:577-580 (2002)					
	21	"Cathflo Activase. Full Prescribing information" 2002 Physicians Desk Reference, Montvale, NJ:Thomas Medical Economics Co. (2002)					

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1989R1Serial No.
10/697,142

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Semba Charles P.Filing Date
30 Oct 2003Group
Not Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

TU	22	Chang et al., "Daily Catheter-directed Single Dosing of t-PA in Treatment of Acute Deep Venous Thrombosis of the Lower Extremity" <u>J. Vasc. Interv. Radiol.</u> 12:247-252 (2001)
	23	Collen, D. et al., "Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog" <u>Thrombosis and Haemostasis</u> 72(1):98-104 (1994)
	24	Cornelius et al., "Adsorption of proteins from infant and adult plasma to biomaterial surfaces" <u>J. Biomed. Mater. Res.</u> 15:622-632 (2000)
	25	Davidian et al., "Initial Results of Reteplase in the Treatment of Acute Lower Extremity Arterial Occlusions" <u>J. Vasc. Interv. Radiol.</u> 11:289-294 (2000)
	26	Dawson et al., "Plasminogen Mutants Activated by Thrombin" <u>Journal of Biological Chemistry</u> 269:15989-15992 (1994)
	27	Decrinis et al., "A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results" <u>European Heart Journal</u> 14:297-305 (1993)
	28	Drescher et al., "Initial Experience with the Combination of Reteplase and Abciximab for Thrombolytic Therapy in Peripheral Arterial Occlusive Disease: A Pilot Study" <u>J. Vasc. Interv. Radiol.</u> 13:37-43 (2002)
	29	Elsharaway and Elzayat, "Early Results of Thrombolysis vs Anticoagulation in Iliofemoral Venous Thrombosis.. A Randomized Clinical Trial" <u>Eur. J. Vasc. Endovasc. Surg.</u> 24:209-214 (2002)
	30	Findlay et al., "Lysis of intraventricular hematoma with tissue plasminogen activator" <u>J. Neurosurg.</u> 74:803-807 (1991)
	31	Graul et al. <u>Xemilifiban; Drugs of the future</u> 22:508-517 (1997)
	32	Hara, T. et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa" <u>Thrombosis and Haemostasis</u> 71(3):314-319 (1994)
	33	Hofmann et al., "GP1Ib-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know" <u>Cardiovasc. Interv. Radiol.</u> 24:361-367 (2001)
	34	Kaiser, "Thrombin and factor Xa inhibitors" <u>Drugs of the Future</u> 23:423-436 (1998)
	35	Kawasaki et al., "Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis" <u>Thromb. Haemost.</u> 79:859-864 (1998)
	36	Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." <u>Proc. Natl. Acad. Sci. USA</u> 91:3670-3674 (1994)
	37	LeBlang et al., "Low-Dose Urokinase Regimen for the Treatment of Lower Extremity Arterial and Graft Occlusions: Experience in 132 cases" <u>J. Vasc. Interv. Radiol.</u> 3:475-483 (1992)
	38	McNamara and Fischer, "Thrombolysis of Peripheral Arterial and Graft Occlusions: Improved Results Using High-Dose Urokinase" <u>Am. J. Radiol.</u> 144:769-775 (1985)
	39	McNamara et al., "Bleeding Associated With Intrathrombus Infusions of r-tPA for Peripheral Arterial and Venous Occlusion" <u>Am. J. Cardiol.</u> 84:37P (1999)
	40	Mewissen et al., "Catheter-directed Thrombolysis for Lower Extremity Deep Venous Thrombosis: Report of a National Multicenter Registry" <u>Radiology</u> 211:39-49 (1999)
	41	Nehme et al., "Tenecteplase for the Lyse and Wait Technique in Recanalization of Thrombosed PTFE Hemodialysis Grafts" <u>J. Vasc. Interv. Radiol.</u> 13:S109 (2002)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

FEB 11 2004

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1989R1

Serial No.

10/697,142

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Semba Charles P.

Filing Date

30 Oct 2003

Group

Not Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

TU	42	Ouriel et al., "A Comparison of Recombinant Urokinase with Vascular Surgery as Initial Treatment for Acute Arterial Occlusion of the Legs" <u>New England J. of Medicine</u> 16:1105-1111 (1998)
	43	Ouriel et al., "Complications Associated with the Use of Urokinase and Recombinant Tissue Plasminogen Activator for Catheter-directed Peripheral Arterial and Venous Thrombolysis" <u>J. Vasc. Interv. Radiol.</u> 11:295-298 (2000)
	44	Ouriel et al., "Reteplase in the Treatment of Peripheral Arterial and Venous Occlusions: A Pilot Study" <u>J. Vasc. Interv. Radiol.</u> 11:849-854 (2000)
	45	Patel et al., "SCVIR Reporting Standards for the Treatment of Acute Limb Ischemia with Use of Transluminal Removal of Arterial Thrombus" <u>J. Vasc. Interv. Radiol.</u> 12:559-570 (2001)
	46	Razavi et al., "Initial Clinical Results of Tenecteplase (TNK) in Catheter-Directed Thrombolytic Therapy" <u>J. Endovasc. Ther.</u> 9:593-598 (2002)
	47	Razavi et al., "Initial Clinical Results of Tenecteplase (TNK) in Catheter-Directed Thrombolytic Therapy" <u>J. Vasc. Interv. Radiol.</u> 13(2):S11 (Feb 2002)
	48	Refino et al., "A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen" <u>Thromb. Haemost.</u> 70:313-319 (1993)
	49	"Retavase. Full prescribing information" <u>2002 Physicians Desk Reference</u> , Montvale, NJ:Thomas Medical Economics Co. (2002)
	50	Ricotta et al., "Use and limitations of thrombolytic therapy in the treatment of peripheral arterial ischemia: Results of a multi-institutional questionnaire" <u>J. Vasc. Surg.</u> 6:45-50 (1987)
	51	Scarborough et al., "Eptifibatide" <u>Drugs of the future</u> 23:585-590 (1998)
	52	Semba and Dake, "Iliofemoral Deep Venous Thrombosis: Aggressive Therapy with Catheter-directed Thrombolysis" <u>Radiology</u> 191:487-494 (1994)
	53	Semba et al., "Alteplase and Tenecteplase: Applications in the Peripheral Circulation" <u>Tech. Vasc. Interv. Radiol.</u> 4:99-106 (2001)
	54	Semba et al., "Alteplase as an Alternative to Urokinase" <u>J. Vasc. Interv. Radiol.</u> 11:279-287 (2000)
	55	Semba et al., "Alteplase Stability and Bioactivity after Thrombolysis-Facilitated Rheolytic or High-Speed Maceration Thrombectomy" <u>J. Vasc. Interv. Radiol.</u> 13 2 (Part 2):S76 (Feb 2002)
	56	Semba et al., "Tenecteplase (TNK): Protein Stability and Bioactivity of Thawed or Diluted Solutions Used in Peripheral Thrombolysis" <u>J. Vasc. Interv. Radiol.</u> 13(2):Part 2: S75 (Feb 2002)
	57	Semba et al., "Tenecteplase: Stability and Bioactivity of Thawed or Diluted Solutions Used in Peripheral Thrombolysis" <u>J. Vasc. Interv. Radiol.</u> 14:475-479 (2003)
	58	Semba et al., "Thrombolytic Therapy with Use of Alteplase (rt-PA) in Peripheral Arterial Occlusive Disease: Review of the Clinical Literature" <u>J. Vasc. Interv. Radiol.</u> 11:149-161 (2000)
	59	Shortell et al., "Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion" <u>J. Vasc. Surg.</u> 34:854-859 (2001)
	60	The STILE Investigators, "Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity. The STILE trial" <u>Ann. Surg.</u> 220:251-268 (1994)
↓	61	"STREPTASE. Full prescribing information" <u>Physicians Desk Reference</u> , Montvale, NJ:Thomas Medical Economics Co. (2002)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.